Clinical Cancer Research Unit
The Clinical Cancer Research Unit at Oslo University Hospital is located at two sites; the Norwegian Radium Hospital and Ullevål Hospital. In 1995 the Norwegian Radium Hospital established a separate Clinical Cancer Research Unit to provide optimal facilities for experimental treatment, in particular phase I and II clinical trials. In 2006, the new Cancer Centre at Ullevål University Hospital established a Research Unit for phase II and III trials. Today the two centers coordinate their work and the units perform both investigator-initiated and pharma-initiated trials.
The Clinical Cancer Research Unit has highly trained staff and is fully equipped with all the technology necessary for advanced phase I and phase II trials. The staff includes 5 oncologists, 7 research nurses, 1 secretary and 3 project managers. They all have broad experience in oncology and are specifically trained in clinical trial technology and methodology.
The main focus of the Clinical Cancer Research Unit is to perform high-quality and innovative research which will benefit current and future cancer patients. All studies are carried out in accordance to Good Clinical Practice (GCP) and established Standard Operating Procedures (SOP).
More information about the Clinical Cancer Research Unit
Clinical Cancer Research Unit is part of the Nordic Network for Early Cancer Trials (Nordic NECT)
Contact Information
Clinical Cancer Research Unit
Oslo University Hospital
Ullernchausséen 70
NO-0310 Oslo
Tel: +47 91502770
Headed by Paal Fr. Brunsvig
Christos Samakovlis: The molecular basis of airway maturation in Drosophila
Jan 17, 2012
Latest publications
CRU
Publications in press
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Eur J Cancer (in press)
PubMed 22196968
Defining the Critical Hurdles in Cancer Immunotherapy
J Transl Med, 9 (1), 214 (in press)
PubMed 22168571
Publications 2011
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
PubMed 21473790





Print this page
